MA-PRECISELY
Precisely, the global leader in data integrity, today announced that Etam Group, a major international retailer and leading lingerie brand in France, has implemented its Automate Studio solution across all subsidiaries to support company-wide accounts payable processes. By providing seamless SAP data access to decision-makers in real-time, Automate Studio (formerly Winshuttle Studio) enables Etam’s accounting teams to work autonomously without support from IT personnel, reduce operational costs, and drive greater innovation across the organization.
Business agility is critical in the retail industry, with companies seeking to balance tight margins with the need to innovate and stay competitive. With more pressure than ever to optimize margins through existing operating structures and processes, it comes as no surprise that automation has emerged as a top consideration for retailers in 2024. Retail companies are increasingly seeing the need to simplify and accelerate processes across their major functions to drive business efficiencies, improve customer experience, and stay compliant with an ever-changing regulatory landscape.
“In the retail sector, businesses must stay agile and be able to implement ideas quickly, something which is also incredibly important in accounting,” said Stéphane Delattre, Vice President – Accounting for Europe at Etam Group. “Automate Studio increases our productivity and efficiency, enabling mass data simplification and empowering decision-makers to access trustworthy data in real-time. We call it the ‘miracle product’!”
The Etam Group has an impressive history of driving innovation to optimize infrastructure and provide great customer experience – having invented the concept of just-in-time automatic restocking in 1965. But with presence now in over 1,500 stores located across 57 countries, the retailer needed a solution that would work with its SAP ERP (enterprise resource planning) software and support all the company’s subsidiaries in streamlining their data management.
Automate Studio is the premier Excel-to-SAP solutions platform that enables business users to automate complex SAP business processes and make mass data changes quickly and easily. The platform allows customers to eliminate manual data entries and upload and download SAP data in record time, while simultaneously improving data quality. Automate Studio empowers business teams by reducing their reliance on IT support for automating Excel to SAP processes. Now citizen developers within business teams can create and manage their own solutions faster, while ensuring compliance and security standards are maintained.
“Before we deployed Automate Studio, we manually handled hundreds of invoices a month which could be very time-consuming,” said Delattre. “This practical solution from Precisely has not only increased our internal productivity but has helped us save time. Previously, one invoice took three minutes to create and now Automate Studio facilitates the creation of nearly 600 invoices within 15 minutes. Another example is how drastically it reduced the time needed to add purchasing conditions to orders in SAP – this used to take two days but can now be completed in just two hours.”
“Precisely is committed to helping customers automate their SAP processes to maintain agility, accelerate speed of business, and build the integrity of their data,” said Pat McCarthy, Chief Revenue Officer at Precisely. “As more organizations embark on digital transformation across their core functions, they are realizing the power of process automation, fueled by accurate, consistent, and contextual data to help ensure success.”
Learn more about Precisely Automate Studio.
About Etam Group
One hundred years old, still family-owned and independent, the Etam Group, now a leader in France and internationally, is a key player in innovative and creative lingerie and fashion. With its identity and historical know-how, the Etam Group cultivates this unique relationship with its customers through its brands Etam, Maison 123, Undiz Livy and Ysé, and a strong omnichannel presence based on more than 1500 stores in 57 countries. Learn more at https://etam-groupe.com
About Precisely
Precisely is the global leader in data integrity, providing accuracy, consistency, and context in data for 12,000 customers in more than 100 countries, including 99 of the Fortune 100. Precisely’s data integration, data quality, data governance, location intelligence, and data enrichment products power better business decisions to create better outcomes. Learn more at www.precisely.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240228517820/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Natus Sensory Appoints Arne Boye Nielsen to Board of Directors8.1.2026 08:00:00 CET | Press release
Natus Sensory, a global leader in sensory and diagnostic solutions, today announced the appointment of Arne Boye Nielsen to its Board of Directors, effective January 1, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107392331/en/ Arne Boye Nielsen Arne brings more than 30 years of executive leadership experience in diagnostics and medical technology, most notably as President of Demant Diagnostics, where he built and scaled the business into a global leader over three decades. During his tenure, Arne played a central role in shaping Demant Diagnostics’ long-term strategy, portfolio expansion, and international growth, establishing it as a cornerstone of Demant’s global healthcare footprint. In addition to his executive leadership background, Arne brings extensive board experience. His deep expertise across diagnostics, governance, and value creation will further strengthen Natus Sensory’s Board as the company contin
4Moving Biotech Receives FDA IND Clearance for 4P004, Strengthening Its Position as a Leading Innovator in Disease-Modifying Osteoarthritis Therapeutics8.1.2026 07:30:00 CET | Press release
FDA IND clearance enabling the worldwide expansion of the INFLAM MOTION Phase 2a trial, involving major U.S. sites Advancing the first clinical proof of concept in OA with a first-in-class intra-articular GLP-1 agonist A holistic clinical strategy design establishing the foundation for a future accelerated approval pathway 4Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for 4P004, enabling the expansion of the Phase 2a INFLAM MOTION clinical trial into the United States (US). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107798042/en/ 4Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. F
Organon Enters into a Commercialization Agreement for Daiichi Sankyo’s Nilemdo®in France, Denmark, Iceland, Sweden, Finland and Norway8.1.2026 07:30:00 CET | Press release
The agreement builds on Organon’s cardiovascular disease portfolio, leveraging expertise to expand access to new treatments for patients with dyslipidemia, especially statin-intolerant patients.This collaboration addresses a critical gap in care that disproportionately affects women, who are at a 47% higher risk of developing statin intolerance compared to men.i Organon today announced that it has entered into an agreement with Daiichi Sankyo Europe to commercialize Nilemdo® (bempedoic acid) in France, Denmark, Iceland, Sweden, Finland and Norway. Nilemdo® is a new, first-in-class drug indicated for patients with high cholesterol and cardiovascular disease risk. It provides an alternative treatment for patients that cannot be treated effectively with statins.ii “This collaboration combines Organon’s commercial agility with Daiichi Sankyo’s expertise in cardiovascular innovation to bring Nilemdo® to patients in France, Denmark, Iceland, Sweden, Finland and Norway,” says Thibault Crosnie
Prodapt Earns ISO 42001 Certification, the New Global Benchmark for Responsible Enterprise AI8.1.2026 07:00:00 CET | Press release
Prodapt today announced that it has been awarded the ISO 42001 certification, the world’s first and the only global standard for AI Management Systems (AIMS). Marking a significant milestone in its journey, Prodapt is setting a higher benchmark to deliver secure, ethical, and scalable AI for global enterprises. ISO 42001 lays a rigorous framework for governing AI across strategy, technology, and operations. The certification, awarded by an independent accredited body, validates Prodapt’s enterprise-grade AI management framework, including executive-led oversight, strong technology foundations, and disciplined operational processes. These measures ensure AI systems are responsibly designed, deployed, monitored, and evolved throughout their lifecycle. The evaluation emphasizes risk management, ethical AI practices, transparency, and scalability, confirming Prodapt’s ability to proactively identify and mitigate risks while ensuring accountability in AI-driven outcomes. Human-in-the-loop c
Azafaros to Present at J.P. Morgan’s 44th Annual Healthcare Conference8.1.2026 07:00:00 CET | Press release
Azafaros, a company building a portfolio to become a leader in lysosomal storage disorders with the goal of addressing neurological symptoms, today announced that it will present at J.P. Morgan’s 44th Annual Healthcare Conference on Thursday, January 15. The company’s presentation will begin at 9:30 am PT/12:30 am ET/6:30 am CET. The presentation will focus on the company’s lead product, nizubaglustat, a potential treatment for rare lysosomal storage disorders with neurological involvement including GM1/GM2 gangliosidoses and Niemann-Pick type C disease ((NPC). Two pivotal Phase 3 studies investigating nizubaglustat in GM1/GM2 gangliosidoses and NPC are currently enrolling, with data expected in 2027. The studies build on positive data from a robust clinical program including the Phase 2 RAINBOW study and the PRONTO natural history study. The Phase 3 studies are financed following the company’s successful completion of €132 million series B round completed in 1H 2025. About nizubaglust
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom